DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Medtech (427)

US Opportunities for Alzheimer’s Imaging Agents 2014

US Opportunities for Alzheimer’s Imaging Agents 2014

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.


The first Alzheimer's imaging agent, Amyvid, became available in the US in April 2012 and, though the market for these products was valued at less than $3 million in 2013, increased coverage and the launch of the first DMT for AD will help the market to experience rapid expansion through 2022.



This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for Alzheimer's imaging agents in the US across a 10-year period.

  • Pub Date: December 2013

Request report

Related reports:
You may also be interested in: